Articles dans des revues avec comité de lecture (103)
  1. 13. Furgiuele, S., Descamps, G., Cascarano, L., Boucq, A., Dubois, C., Journé, F., & Saussez, S. (2022). Dealing with Macrophage Plasticity to Address Therapeutic Challenges in Head and Neck Cancers. International journal of molecular sciences, 23(12), 6385. doi:10.3390/ijms23126385
  2. 14. Najem, A., Soumoy, L., Sabbah, M., Krayem, M., Awada, A., Journé, F., & Ghanem, G. E. (2022). Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells, 11(7), 1157. doi:10.3390/cells11071157
  3. 15. Yanni, A., Buset, T., Bouland, C., Loeb, I., Lechien, J., Rodriguez, A., Journé, F., Saussez, S., & Dequanter, D. (2022). Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck cancer with lung metastasis: a retrospective study. European archives of oto-rhino-laryngology. doi:10.1007/s00405-022-07274-1
  4. 16. De Bakker, T., Journé, F., Descamps, G., Saussez, S., Dragan, T., Atassi, G., Krayem, M., & Van Gestel, D. (2022). Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. Frontiers in oncology, 11. doi:10.3389/fonc.2021.799993
  5. 17. Najem, A., Wouters, J., Krayem, M., Rambow, F., Sabbah, M., Sales, F., Awada, A., Aerts, S., Journé, F., Marine, J.-C., & Ghanem, G. E. (2021). Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. Frontiers in oncology, 11, 780654. doi:10.3389/fonc.2021.780654
  6. 18. Berehab, M., Rouas, R., Akl, H., Duvillier, H., Journé, F., Fayyad Kazan, H., Ghanem, G. E., Bron, D., Lewalle, P., & Merimi, M. (2021). Apoptotic and non-apoptotic modalities of thymoquinone-induced lymphoma cell death: Highlight of the role of cytosolic calcium and necroptosis. Cancers (Basel), 13(14), 3579. doi:10.3390/cancers13143579
  7. 19. Sabbah, M., Krayem, M., Najem, A., Sales, F., Miller, W. W., Del Rincón, S. S., Awada, A., Ghanem, G. E., & Journé, F. (2021). Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-kit. Molecular cancer research, 19(7), 1221-1233. doi:10.1158/1541-7786.MCR-20-1040
  8. 20. Lechien, J., Chiesa-Estomba, C. M., Beckers, E., Mustin, V., Ducarme, M., Journé, F., Marchant, A., Jouffe, L., Barillari, M. R., Cammaroto, G., Circiu, M., Hans, S., & Saussez, S. (2021). Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. Journal of internal medicine. doi:10.1111/joim.13209
  9. 21. Gheysen, L., Soumoy, L., Trelcat, A., Verset, L., Journé, F., & Saussez, S. (2021). New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer. Cells, 10(5). doi:10.3390/cells10051112
  10. 22. Kindt, N., Journé, F., Carlier, S., Trelcat, A., Scalia, A., & Saussez, S. (2021). Effect of oxidized low-density lipoprotein on head and neck squamous cell carcinomas. Biomedicines, 9(5), 513. doi:10.3390/biomedicines9050513
  11. 23. Sabbah, M., Najem, A., Krayem, M., Awada, A., Journé, F., & Ghanem, G. E. (2021). Rtk inhibitors in melanoma: From bench to bedside. Cancers (Basel), 13(7), 1685. doi:10.3390/cancers13071685
  12. 24. Lechien, J., Chiesa-Estomba, C. M., Vaira, L., De Riu, G., Cammaroto, G., Chekkoury-Idrissi, Y., Circiu, M., Distinguin, L., Journé, F., de Terwangne, C., Machayekhi, S., Barillari, M. R., Calvo-Henriquez, C., Hans, S., & Saussez, S. (2021). Correction to: Epidemiological, otolaryngological, olfactory and gustatory outcomes according to the severity of COVID-19: a study of 2579 patients (European Archives of Oto-Rhino-Laryngology, (2021), 278, 8, (2851-2859), 10.1007/s00405-020-06548-w). European archives of oto-rhino-laryngology. doi:10.1007/s00405-021-06656-1
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 Suivant >>